Souders Financial Advisors Buys 1,090 Shares of Amgen Inc. (NASDAQ:AMGN)

Souders Financial Advisors raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 7.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,174 shares of the medical research company’s stock after purchasing an additional 1,090 shares during the period. Souders Financial Advisors’ holdings in Amgen were worth $4,889,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in AMGN. Edmond DE Rothschild Holding S.A. raised its position in shares of Amgen by 63.5% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 2,230 shares of the medical research company’s stock valued at $634,000 after acquiring an additional 866 shares during the period. Angeles Wealth Management LLC acquired a new stake in Amgen during the 1st quarter worth approximately $210,000. Delta Investment Management LLC raised its holdings in Amgen by 8.6% during the 1st quarter. Delta Investment Management LLC now owns 1,842 shares of the medical research company’s stock worth $524,000 after buying an additional 146 shares during the period. Beacon Investment Advisory Services Inc. raised its holdings in Amgen by 41.3% during the 1st quarter. Beacon Investment Advisory Services Inc. now owns 41,950 shares of the medical research company’s stock worth $11,927,000 after buying an additional 12,268 shares during the period. Finally, Kingsview Wealth Management LLC raised its holdings in Amgen by 10.1% during the 1st quarter. Kingsview Wealth Management LLC now owns 63,452 shares of the medical research company’s stock worth $18,041,000 after buying an additional 5,819 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Down 7.1 %

AMGN opened at $298.84 on Wednesday. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The company has a market capitalization of $160.64 billion, a P/E ratio of 38.26, a P/E/G ratio of 2.87 and a beta of 0.60. The stock has a fifty day moving average of $323.37 and a 200-day moving average of $318.07.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.96 earnings per share. On average, equities analysts expect that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Analyst Ratings Changes

Several brokerages have recently weighed in on AMGN. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price target on shares of Amgen in a research note on Tuesday. Bank of America raised their price target on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Oppenheimer reaffirmed an “outperform” rating and set a $380.00 price target on shares of Amgen in a research note on Wednesday, August 7th. Finally, William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average price target of $333.50.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.